Characterization of ARC, apoptosis repressor interacting with CARD, in normal and dystrophin-deficient skeletal

S Abmayr1, R W Crawford, J S Chamberlain

  • 1Department of Neurology, University of Washington School of Medicine, Seattle, WA 98195-7720, USA.

Human Molecular Genetics
|December 3, 2003
PubMed

Insights

Apoptosis repressor with caspase recruitment domain (ARC) does not alleviate Duchenne muscular dystrophy pathology in mice. Studies show ARC expression is normal in dystrophic muscles, and its overexpression does not prevent muscle breakdown.

Area of Science:

  • Biochemistry
  • Genetics
  • Cell Biology

Background:

  • Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder causing progressive muscle weakness due to dystrophin absence.
  • Dystrophic muscles exhibit oxidative stress and altered calcium homeostasis, contributing to myofiber loss via necrosis and apoptosis.
  • Apoptosis repressor with caspase recruitment domain (ARC) is a muscle protein that inhibits apoptosis and oxidative stress.

Purpose of the Study:

  • To investigate the role of ARC in protecting muscle fibers from dystrophic damage.
  • To clone and characterize murine ARC and analyze its expression in normal and dystrophic mouse models.

Main Methods:

  • Cloning and characterization of murine ARC.
  • Analysis of ARC expression levels and localization in normal and mdx (dystrophic) mouse muscle.
  • Overexpression of ARC in transgenic mdx mice to assess its therapeutic potential.

Main Results:

  • Murine ARC is highly expressed in striated muscle with fiber-type restricted patterns.
  • ARC expression levels were normal in mdx mice, with minor alterations in intracellular localization.
  • Overexpression of ARC in transgenic mdx mice did not ameliorate skeletal muscle pathology.

Conclusions:

  • Misregulation of ARC-regulated pathways is not a significant factor in myofiber death in Duchenne muscular dystrophy.
  • ARC does not appear to be a viable therapeutic target for mitigating dystrophic pathology.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...